Third Edition of Tommy Hilfiger Fashion Frontier Challenge Highlights Six Global Entrepreneurs Accelerating Change in the Fashion Industry
13.12.2021 17:30:00 EET | Business Wire | Press release
Tommy Hilfiger, which is owned by PVH Corp. [NYSE: PVH], is pleased to announce the six finalists of the 2021 Tommy Hilfiger Fashion Frontier Challenge, who were carefully selected from over 430 applications received from startups and scaleups globally. Building on Tommy Hilfiger’s sustainability vision to Waste Nothing and Welcome All, the third edition of the program strives to continue amplifying and supporting black, indigenous and people of color (BIPOC) entrepreneurs who are working to advance their communities, while fostering a more inclusive future of fashion. With the need to drive impact in the industry more important than ever, the third year of the Tommy Hilfiger Fashion Frontier Challenge was done completely virtual to overcome the ongoing restrictions and challenges of the COVID-19 pandemic.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211213005214/en/
Over a multi-step year-long process, applications were thoroughly reviewed by internal and external experts based on a dedicated set of criteria including potential social impact and market growth. The six finalists will pitch their business ideas to a jury panel consisting of business and sustainability leaders at the virtual global Tommy Hilfiger Fashion Frontier Challenge final event on January 12-13, 2022.
“The Tommy Hilfiger Fashion Frontier Challenge embodies our long-standing mission to harness the power of fashion to foster inclusivity, representation and change,” said Tommy Hilfiger. “Our industry will only move forward with new, fresh ideas that challenge how we think, build and create. As a brand, it’s vital we use our platform to give entrepreneurs like our finalists a voice and opportunity to create real and long-lasting impact.”
The six finalists are:
- Clothes to Good: A South African-based social enterprise that creates micro-business opportunities and jobs for people with disabilities and their families, especially mothers, through textile recycling.
- Haelixa: A Switzerland-based product traceability technology that aims to accelerate the global transition to transparent consumer goods supply chains.
- MAFI MAFI: An Ethiopia-based sustainable fashion brand that crafts ready-to-wear collections, preserving ancient traditions and empowering marginalized artisans.
- Lalaland: A Netherlands-based platform that uses artificial intelligence to generate customized and inclusive synthetic models of different ethnicities, ages and sizes, all with over 35 pose variations.
- SOKO: This Kenya-based jewelry business uses mobile technology to connect marginalized Kenyan artisans directly to the global marketplace via a mobile platform.
- UZURI K&Y: This Rwandan-based eco-friendly shoe brand uses recycled car tires from sub-Saharan Africa and employs local youth, equipping them with skills and economic independence.
The jurors overseeing the final event are:
- Mr. Tommy Hilfiger
- Martijn Hagman, CEO, Tommy Hilfiger Global and PVH Europe
- Yara Shahidi, award-winning actress, producer, and change agent.
- Esther Verburg, EVP, Sustainable Business and Innovation, Tommy Hilfiger Global and PVH Europe
- Adrian Johnson, Entrepreneur, Adjunct Professor of Entrepreneurship, Technology and Media at INSEAD
- Katrin Ley, Managing Director of Fashion for Good and Founding Curator of the Amsterdam Global Shapers Hub
- Yvonne Bajela, founding member and principal at investment firm Impact X Capital
With the support of Tommy Hilfiger and INSEAD subject matter experts, the six finalists have developed and refined their business plans, which they will present at the final event. Arooj Aftab, content creator, illustrator, writer and founder of #DonewithDiversity, will host the final event where the jury will award €200,000 to be split between two chosen winners in order to support their ventures. The winners will also receive a year-long mentorship with both Tommy Hilfiger and INSEAD experts, as well as a place in the INSEAD Social Entrepreneurship Program (ISEP). An additional €15,000 will be awarded to the finalist who Tommy Hilfiger associates select as their 'Audience Favorite' vote.
“As key players in the fashion industry, it is our responsibility to support, empower and encourage inclusivity. The Tommy Hilfiger Fashion Frontier Challenge is a testament of our commitment to make a meaningful and lasting contribution towards a better fashion industry,” said Martijn Hagman, CEO, Tommy Hilfiger Global and PVH Europe. “It is in our nature to drive change, even in the most challenging of times. We are proud to continue amplifying the ideas of entrepreneurs that are creating the fashion landscape we want, and need, to see.”
Tommy Hilfiger’s mission is to become a leading sustainable designer lifestyle company that Wastes Nothing and Welcomes All, through how it creates its product, manages its operations and connects with its communities and stakeholders. More information about Tommy Hilfiger’s sustainability journey, which is powered by PVH’s Forward Fashion strategy, can be found on https://global.tommy.com/en_int/about-us-corporate-responsibility.
More information about the Tommy Hilfiger Fashion Frontier Challenge is available here: https://responsibility.pvh.com/tommy/fashion-frontier-challenge/. Friends and followers of the brand are invited to join the conversation on social media using #TommyHilfiger and @TommyHilfiger.
About Tommy Hilfiger
With a brand portfolio that includes TOMMY HILFIGER and TOMMY JEANS, Tommy Hilfiger is one of the world’s most recognized premium designer lifestyle groups. Its focus is designing and marketing high-quality men’s tailored clothing and sportswear, women’s collection apparel and sportswear, kidswear, denim collections, underwear (including robes, sleepwear and loungewear), footwear and accessories. Through select licensees, Tommy Hilfiger offers complementary lifestyle products such as eyewear, watches, fragrance, swimwear, socks, small leather goods, home goods and luggage. The TOMMY JEANS product line consists of jeanswear and footwear for men and women, accessories, and fragrance. Merchandise under the TOMMY HILFIGER and TOMMY JEANS brands is available to consumers worldwide through an extensive network of TOMMY HILFIGER and TOMMY JEANS retail stores, leading specialty and department stores, select online retailers, and at tommy.com.
About PVH Corp.
PVH is one of the world’s largest and most admired fashion companies, connecting with consumers in over 40 countries. Our global iconic brands include Calvin Klein and TOMMY HILFIGER . Our 140-year history is built on the strength of our brands, our team and our commitment to drive fashion forward for good. That's the Power of Us. That’s the Power of PVH.
Follow us on Facebook , Instagram, Twitter and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211213005214/en/
Contact information
Tommy Hilfiger Media
Virginia Ritchie
Vice President, Global Communications
E-mail: virginia.ritchie@tommy.com
Tel: +31 6 4318 4870
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
